This exciting collaboration will provide a unique opportunity to combine Genmab’s innovative bispecific antibody technologies with Bolt’s powerful, advanced ISAC technology to develop targeted antibody products with the potential to transform cancer treatment
Our deep resources, commitment, and knowledge within the Nan Fung Life Sciences family of investment companies make us the ideal partners to scientists, entrepreneurs, and corporations around the world. With a diverse set of experiences, skills, and a track record in company formation, venture capital, and scientific innovation, we focus on delivering opportunities to investors who seek to benefit from long-term value.
Nan Fung Life Sciences
We have an important job to do. Find your role.
Exscientia announces second molecule created using AI from Sumitomo Dainippon Pharma collaboration to enter Phase 1 clinical trial
Second clinical molecule from Exscientia collaboration with Sumitomo Dainippon Pharma to begin Phase 1 trials in United States.
While hearing health issues have historically been under-emphasized, it’s estimated that 360 million people suffer from some form of hearing loss (over 5% of the global population) worldwide…
BOSTON, Feb. 04, 2021 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics….